Form 4: Immuneering Director Robert J. Carpenter Receives Options

Director Robert J. Carpenter was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Summary

• Director Robert J. Carpenter acquired 33,350 stock options in Immuneering Corp (IMRX).
• The options have an exercise price of $4.12 per share.
• The grant date is June 11, 2026, with an expiration date of June 11, 2036.
• Vesting occurs in equal monthly installments over one year, starting July 11, 2026, and completing by June 11, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying Class A Common Stock.
• The exercise price of $4.12 may be subject to market fluctuations relative to the future trading price of IMRX.

Future Outlook

The options vest over a one-year period, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board alignment with long-term corporate milestones and clinical development timelines.

Comparison to Industry Standards

• The one-year vesting schedule is consistent with standard corporate governance practices for director equity compensation in small-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders if options are exercised.

Next Steps

• Vesting of options to commence on July 11, 2026.

Key Dates

Keywords

Immuneering, IMRX, Form 4, Director Compensation, Stock Options, Insider Trading